Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy

ERYILMAZ M. K., Mutlu H., SALIM D. K., MUSRI F. Y., Tural D., Bassorgun I., ...More

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.22, no.3, pp.533-536, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 22 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1177/1078155215572930
  • Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.533-536
  • Keywords: Melanoma, ipilimumab, cytotoxic T-lymphocyte antigen-4, radiotherapy, dermatitis, RADIATION-THERAPY, LOCAL RADIATION, HIGH-RISK, ADJUVANT RADIOTHERAPY, MELANOMA, INHIBITION, LYMPHADENECTOMY, IMMUNOTHERAPY, ANTIBODY, PATIENT
  • Akdeniz University Affiliated: Yes

Abstract

Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.